Multiple endogenous glycan-processing enzymes and pathways

Multiple endogenous glycan-processing enzymes and pathways refer to the collective enzymatic machinery, including glycosidases and glycosyltransferases, that orchestrates the synthesis, modification, and degradation of glycans on glycoproteins and glycolipids (Varki et al., 2017). These pathways are integral to cellular homeostasis, influencing protein folding, stability, and cell-surface interactions. Dysregulation of these enzymes is a hallmark of several metabolic and genetic disorders, most notably lysosomal storage diseases like Gaucher disease, where substrate accumulation leads to systemic organ damage (NCBI PubChem, CID 5164). In the context of pharmacology, this target group is often addressed through substrate reduction therapy or competitive inhibition of carbohydrate-digesting enzymes. Drugs such as miglustat demonstrate the therapeutic potential of modulating these pathways, though their lack of absolute specificity often results in a broad range of gastrointestinal and neurological side effects (FDA Zavesca Label). Understanding the interplay between these multiple enzymes is crucial for developing more selective glycomimetic drugs with improved safety profiles.

Other names

Glycan-modifying enzymesGlycosylation pathwaysGlycosidases and glycosyltransferasesEndogenous glycan processing

Competitive inhibition of glycosyltransferases or glycosidases to reduce the rate of substrate synthesis (substrate reduction therapy) or to slow the breakdown of complex carbohydrates into glucose.